JP2024527020A - 抗原結合分子の組合せ - Google Patents
抗原結合分子の組合せ Download PDFInfo
- Publication number
- JP2024527020A JP2024527020A JP2024504772A JP2024504772A JP2024527020A JP 2024527020 A JP2024527020 A JP 2024527020A JP 2024504772 A JP2024504772 A JP 2024504772A JP 2024504772 A JP2024504772 A JP 2024504772A JP 2024527020 A JP2024527020 A JP 2024527020A
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- terminus
- domain
- peptide linker
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21187924 | 2021-07-27 | ||
| EP21187924.2 | 2021-07-27 | ||
| PCT/EP2022/071060 WO2023006809A1 (en) | 2021-07-27 | 2022-07-27 | Combinations of antigen binding molecules |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527020A true JP2024527020A (ja) | 2024-07-19 |
| JP2024527020A5 JP2024527020A5 (cg-RX-API-DMAC7.html) | 2025-09-02 |
Family
ID=77103832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024504772A Pending JP2024527020A (ja) | 2021-07-27 | 2022-07-27 | 抗原結合分子の組合せ |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250101103A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4377347A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024527020A (cg-RX-API-DMAC7.html) |
| CN (1) | CN117715939A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022318255A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3227537A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023006809A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3217894A1 (en) * | 2021-05-28 | 2022-12-01 | Gernot Stuhler | Recombinant proteinaceous binding molecules |
| WO2025036892A1 (en) | 2023-08-14 | 2025-02-20 | Morphosys Ag | Cycat halfbody molecules comprising sterically occluding moieties |
| WO2025082777A1 (en) | 2023-10-17 | 2025-04-24 | Morphosys Ag | Dual-targeting of muc16 and mesothelin co-expressing tumor cells by functional complementation of cycat® halfbody molecules |
| WO2025237931A1 (en) * | 2024-05-15 | 2025-11-20 | F. Hoffmann-La Roche Ag | Recombinant binding proteins with conditionally activatable t cell and nk cell recruiting effector domains |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017536829A (ja) * | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3および腫瘍抗原に結合するヘテロ二量体抗体 |
| WO2020115115A1 (en) * | 2018-12-05 | 2020-06-11 | Morphosys Ag | Multispecific antigen-binding molecules |
| WO2020216883A1 (en) * | 2019-04-25 | 2020-10-29 | F. Hoffmann-La Roche Ag | Activatable therapeutic multispecific polypeptides with extended half-life |
| JP2021501181A (ja) * | 2017-10-30 | 2021-01-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 単一特異性抗体から多重特異性抗体をインビボ生成させるための方法 |
| JP2021503892A (ja) * | 2017-11-21 | 2021-02-15 | ノバルティス アーゲー | 腫瘍関連抗原に対する三重特異性結合分子及びその使用 |
| WO2021030680A1 (en) * | 2019-08-15 | 2021-02-18 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules for cell targeting and uses thereof |
| JP2021509896A (ja) * | 2018-01-08 | 2021-04-08 | ナンジン レジェンド バイオテック カンパニー,リミテッドNanjing Legend Biotech Co.,Ltd. | 多重特異性抗原結合タンパク質及びその使用方法 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| JP3614866B2 (ja) | 1997-06-12 | 2005-01-26 | リサーチ コーポレイション テクノロジーズ,インコーポレイティド | 人工抗体ポリペプチド |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US20130089554A1 (en) | 2009-12-29 | 2013-04-11 | Emergent Product Development Seattle, Llc | RON Binding Constructs and Methods of Use Thereof |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US9527927B2 (en) | 2011-12-20 | 2016-12-27 | Medimmune, Llc | Modified polypeptides for bispecific antibody scaffolds |
| MX359411B (es) | 2012-01-13 | 2018-09-27 | Univ Wuerzburg J Maximilians | Complementación funcional bipartita inducida por antígenos, dual. |
| WO2013157953A1 (en) | 2012-04-20 | 2013-10-24 | Merus B.V. | Methods and means for the production of ig-like molecules |
| EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| WO2016087416A1 (en) * | 2014-12-03 | 2016-06-09 | F. Hoffmann-La Roche Ag | Multispecific antibodies |
| HUE054131T2 (hu) | 2015-11-19 | 2021-08-30 | Revitope Ltd | Funkcionális ellenanyag-fragmens-komplementáció nemkívánatos sejtek elpusztítására szolgáló kétkomponensû rendszerben |
| WO2019077092A1 (en) | 2017-10-20 | 2019-04-25 | F. Hoffmann-La Roche Ag | METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES |
| WO2019199916A1 (en) * | 2018-04-13 | 2019-10-17 | Eli Lilly And Company | Fab-based trispecific antibodies |
| KR102956533B1 (ko) | 2018-07-02 | 2026-04-24 | 더 제너럴 하스피탈 코포레이션 | 항체 종양-표적화 조립 복합체 |
| WO2020023553A1 (en) * | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| EP3959237A1 (en) | 2019-04-25 | 2022-03-02 | F. Hoffmann-La Roche AG | Therapeutic multispecific polypeptides activated by polypeptide chain exchange |
| JP7812230B2 (ja) | 2019-04-25 | 2026-02-09 | エフ. ホフマン-ラ ロシュ アーゲー | ポリペプチド鎖交換による抗体由来ポリペプチドの生成 |
| CA3138854A1 (en) | 2019-05-02 | 2020-11-05 | The General Hospital Corporation | Teac and attac immunooncology compositions and methods |
| JP7851303B2 (ja) | 2020-09-24 | 2026-04-24 | モルフォシス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | ヒトcd3イプシロンに結合する新規なヒト抗体 |
-
2022
- 2022-07-27 AU AU2022318255A patent/AU2022318255A1/en not_active Abandoned
- 2022-07-27 WO PCT/EP2022/071060 patent/WO2023006809A1/en not_active Ceased
- 2022-07-27 JP JP2024504772A patent/JP2024527020A/ja active Pending
- 2022-07-27 CA CA3227537A patent/CA3227537A1/en active Pending
- 2022-07-27 US US18/291,283 patent/US20250101103A1/en active Pending
- 2022-07-27 CN CN202280052700.8A patent/CN117715939A/zh active Pending
- 2022-07-27 EP EP22755197.5A patent/EP4377347A1/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017536829A (ja) * | 2014-11-26 | 2017-12-14 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3および腫瘍抗原に結合するヘテロ二量体抗体 |
| JP2021501181A (ja) * | 2017-10-30 | 2021-01-14 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 単一特異性抗体から多重特異性抗体をインビボ生成させるための方法 |
| JP2021503892A (ja) * | 2017-11-21 | 2021-02-15 | ノバルティス アーゲー | 腫瘍関連抗原に対する三重特異性結合分子及びその使用 |
| JP2021509896A (ja) * | 2018-01-08 | 2021-04-08 | ナンジン レジェンド バイオテック カンパニー,リミテッドNanjing Legend Biotech Co.,Ltd. | 多重特異性抗原結合タンパク質及びその使用方法 |
| WO2020115115A1 (en) * | 2018-12-05 | 2020-06-11 | Morphosys Ag | Multispecific antigen-binding molecules |
| WO2020216883A1 (en) * | 2019-04-25 | 2020-10-29 | F. Hoffmann-La Roche Ag | Activatable therapeutic multispecific polypeptides with extended half-life |
| WO2021030680A1 (en) * | 2019-08-15 | 2021-02-18 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules for cell targeting and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022318255A1 (en) | 2024-01-18 |
| CN117715939A (zh) | 2024-03-15 |
| US20250101103A1 (en) | 2025-03-27 |
| CA3227537A1 (en) | 2023-02-02 |
| WO2023006809A1 (en) | 2023-02-02 |
| EP4377347A1 (en) | 2024-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7323659B2 (ja) | ヘテロ二量体タンパク質 | |
| JP7025388B2 (ja) | 新規異種二量体タンパク質 | |
| US20250101103A1 (en) | Combinations of antigen binding molecules | |
| US20220041719A1 (en) | Multispecific antigen-binding molecules | |
| EP1786918A2 (en) | Novel tetravalent bispecific antibody | |
| JP2026515641A (ja) | 一体型アゴニスト抗体 | |
| WO2025036892A1 (en) | Cycat halfbody molecules comprising sterically occluding moieties | |
| HK40026815B (en) | Heterodimeric proteins | |
| HK40027796B (en) | Novel heterodimeric proteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20250703 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20250707 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250725 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250725 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20260421 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20260423 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20260713 |